News from the cancer side, January 9



News from the corporate side

Growing shortage of gastroenterologists to affect screening capacity for #2 cancer killer
Last January 7, 2009, data from researched conducted by the Lewin Group as commissioned by medical technology company Olympus, were presented in a telenews event. The study report entitled “The Impact of Improved Colorectal Cancer Screening Rates on Adequacy of Future Supply of Gastroenterologists that the US” concludes that the US is facing a shortage of gastroenterologists (GIs). This shortage can have some serious consequences in the screening of colorectal cancer. News event speakers were: F. Mark Gumz, President and CEO, Olympus Corporation of the Americas; Tim Dall, vice president and lead study author, The Lewin Group; Robert Reinhardt, Chief of Strategy, Medical and Surgical Business, Olympus America; and Dr. Patrick Okolo, Chief of Endoscopy, The Johns Hopkins University School of Medicine. The report is available at www.olympusamerica.com/crcadvocacy/.

News from the laboratory

Rat embryonic stem cells created  

Finally, rat embryonic stem cells which are pluripotent. This means, there will soon be a hordes of genetically modified rats avialble for research. Well, it’s been done in mice, and in fact, has been for many years now, so what is the big deal? Well, for one thing rats are bigger and their size makes them better animal models in the lad for certain human diseases than their smaller cousins. This breakthrough was achieved by researchers at the University of Cambridge, UK, University of Southern California, Los Angeles.

News from the health authorities

New tool developed to predict colorectal cancer risk

The National Institutes for Health has introduced a new online tool for assessing colorectal cancer risk in adults 50 and older. The risk assessment tool is available on the NCI Web site at www.cancer.gov/colorectalcancerrisk, and people using this tool should work with their health care providers to interpret the results.

News from the drug regulators

FDA approves drug for patients with advanced prostate cancer

A new drug approved just in time for the New Year. It has been years since we’ve seen a drug for prostate cancer. Welcome degarelix, a gonadotropin releasing hormone (GnRH) receptor inhibitor. A common treatment for prostate cancer are hormonal treatments and these initially cause increase in testosterone levels but they drop, a surge that can actually stimulate tumor growth rather than inhibit it. Degarelix doesn’t do this but “slows the growth and progression of prostate cancer by suppressing testosterone, which plays an important role in the continued growth of prostate cancer.

Photo credit: stock.xchng

Related Posts with Thumbnails
Print Friendly

Speak Your Mind

*


*

NOTE: The contents in this blog are for informational purposes only, and should not be construed as medical advice, diagnosis, treatment or a substitute for professional care. Always seek the advice of your physician or other qualified health professional before making changes to any existing treatment or program. Some of the information presented in this blog may already be out of date.
Read previous post:
CVD Newswatch, January 9

Apologies for failing to bring you the news round up last Friday. Taht was due to technical problems coupled with...

Close